On this page of StockholderLetter.com we present the latest annual shareholder letter from Neuraxis, INC — ticker symbol NRXS. Reading current and past NRXS letters to shareholders can bring important insights into the investment thesis.
NRXS Shareholder/Stockholder Letter Transcript:
NEURAXIS, INC. 2023 ANNUAL REPORT Neuraxis, Inc. Board of Directors and Executive Officers as of June 28, 2024 BOARD OF DIRECTORS Name Principal Occupation or Employment Brian Carrico President, Chief Executive Officer, and Director, of Neuraxis, Inc. Co-founder of Neuraxis, Inc. National Sales Manager of Terumo Interventional Systems President, BCBS of Indiana at Anthem, Inc. President and Chief Financial Officer of Capri Communities and Bridges Home Healthcare Dr. Christopher Robin Brown Bradley Mitch Watkins Beth Keyser Kristin Ferge EXECUTIVE OFFICERS Name Principal Occupation or Employment Brian Carrico Timothy Henrichs Dr. Adrian Miranda Dr. Thomas Carrico Chief Executive Officer Chief Financial Officer Chief Medical Officer, Senior Vice President of Science and Technology Chief Regulatory Officer, Compliance Officer and Privacy Officer This Annual Report contains forward-looking statements. All statements contained in this Annual Report other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements. Please read the section of our Annual Report on Form 10-K entitled Forward-Looking Statements for a discussion of the limitations and risks regarding forward-looking statements made in this Annual Report. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in Part I, Item 1A, Risk Factors of our Annual Report on Form 10-K included herein, which may cause actual results to differ materially from those contained in any forward-looking statements we may make. We undertake no obligation to revise or publicly release the results of any revision to these forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements.7/1/2024 Letter Continued (Full PDF)